Get the Stockscreener App
8.64
0.93%
0.08
After Hours:
8.64
Transcode Therapeutics Inc stock is traded at $8.64, with a volume of 4,447.
It is up +0.93% in the last 24 hours and down -37.25% over the past month.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
See More
Previous Close:
$8.56
Open:
$8.48
24h Volume:
4,447
Relative Volume:
0.03
Market Cap:
$7.92M
Revenue:
-
Net Income/Loss:
$-14.93M
P/E Ratio:
-0.0325
EPS:
-266.137
Net Cash Flow:
$-15.87M
1W Performance:
-6.49%
1M Performance:
-37.25%
6M Performance:
+8.82%
1Y Performance:
-97.54%
1-Day Range:
$8.48
$8.80
1-Week Range:
$8.48
$9.4315
52-Week Range:
$6.1478
$468.44
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
8.64 | 7.85M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
Is TransCode Therapeutics Inc. stock a contrarian buyRecession Risk & Technical Pattern Recognition Alerts - newser.com
TransCode Therapeutics, Inc. (RNAZ) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
MSN Money - MSN
Real time breakdown of TransCode Therapeutics Inc. stock performanceEarnings Growth Report & Free Expert Verified Stock Movement Alerts - newser.com
What technical models suggest about TransCode Therapeutics Inc.’s comeback2025 Dividend Review & Accurate Buy Signal Alerts - newser.com
Can TransCode Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Pullbacks & Daily Market Momentum Tracking - newser.com
Is TransCode Therapeutics Inc. stock resilient to inflationMarket Risk Summary & Long-Term Capital Growth Ideas - newser.com
TransCode Therapeutics Inc. recovery potential after sell offQuarterly Earnings Summary & Long-Term Capital Growth Ideas - newser.com
Will TransCode Therapeutics Inc. stock outperform value stocks2025 Market Sentiment & Breakout Confirmation Trade Signals - newser.com
Why retail investors favor TransCode Therapeutics Inc. stockWeekly Market Outlook & Weekly High Return Stock Opportunities - newser.com
Market reaction to TransCode Therapeutics Inc.’s recent news - newser.com
TransCode Therapeutics appoints Michel Janicot as development officer By Investing.com - Investing.com Nigeria
TransCode Therapeutics appoints Michel Janicot as development officer - Investing.com India
Transcode Therapeutics expands executive team with appointment of Dr. Michel Janicot as Senior Development Officer - MarketScreener
Transcode Therapeutics Expands Executive Team With Appointment Of Dr. Michel Janicot As Senior Development Officer - TradingView
TransCode Appoints Dr. Michel Janicot Senior Development Officer | RNAZ Stock News - Stock Titan
Is a relief rally coming for TransCode Therapeutics Inc. holders2025 Earnings Surprises & Capital Efficiency Focused Strategies - newser.com
Goldman Sachs Group Inc Significantly Reduces Holdings in TransCode Therapeutics Inc - GuruFocus
TransCode Therapeutics Inc. (RNAZ) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
TransCode Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Using Python tools to backtest TransCode Therapeutics Inc. strategies2025 Retail Activity & Real-Time Volume Triggers - newser.com
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):